- Home
- IPSC
as 03-28-2025 4:00pm EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 58.1M | IPO Year: | 2021 |
| Target Price: | $4.67 | AVG Volume (30 days): | 461.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $4.43 | Next Earning Date: | 03-19-2025 |
| Revenue: | $6,589,000 | Revenue Growth: | 194.81% |
| Revenue Growth (this year): | -46.85% | Revenue Growth (next year): | -41.75% |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farid Adrienne | IPSC | Chief Operations Officer | Mar 10 '25 | Sell | $0.62 | 2,359 | $1,450.79 | 131,717 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Mar 10 '25 | Sell | $0.62 | 2,235 | $1,374.53 | 1,190,310 | |
| Russotti Gregory | IPSC | See Remarks | Mar 10 '25 | Sell | $0.62 | 2,360 | $1,451.40 | 272,573 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Mar 10 '25 | Sell | $0.62 | 1,240 | $762.60 | 315,556 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Feb 18 '25 | Sell | $0.78 | 34,712 | $27,179.50 | 1,190,310 | |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 3 '25 | Sell | $0.78 | 1,054 | $822.12 | 131,717 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Feb 3 '25 | Sell | $0.78 | 351 | $273.78 | 315,556 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
5 days ago
Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating
Simply Wall St.
8 days ago
Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
9 days ago
Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating
Zacks
10 days ago
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates
GlobeNewswire
10 days ago
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
MT Newswires
3 months ago
Piper Sandler Adjusts Price Target on Century Therapeutics to $4 From $12, Keeps Overweight Rating
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.